What is the FDA-approved Tregzi therapy for preventing GVHD in blood cancer transplants?

Tregzi is the first regulatory T cell-based immunotherapy approved by the FDA to improve chronic graft-versus-host disease-free survival in adults with blood cancers undergoing allogeneic stem cell transplants. It combines donor-derived stem, progenitor, and T cells, achieving significantly lower GVHD rates and marking a shift toward immune modulation therapies.